PHS
RCUS icon

PFM Health Sciences’s Arcus Biosciences RCUS Stock Holding History

PFM Health Sciences’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-237,300
Closed -$6.16M – 105
2020
Q4 		$6.16M Sell
237,300
-2,700
-1% -$65.4K 0.22% 77
2020
Q3 		$4.11M Buy
+240,000
New +$5.36M 0.19% 71

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

PFM Health Sciences's RCUS Position: Q2 2026 in Review

PFM Health Sciences opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 152,129 shares worth $4.69M. The stake represents 0.4% of the portfolio and ranks #70 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in RCUS as recently as Q3 2023.

PFM Health Sciences first reported a position in RCUS in Q1 2018 and has held it in 20 quarters since. The position peaked at $139M in Q4 2021. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • PFM Health Sciences held 152,129 shares of Arcus Biosciences worth $4.69M as of Q2 2026.
  • Arcus Biosciences was a new PFM Health Sciences position in Q2 2026.
  • Arcus Biosciences made up 0.4% of PFM Health Sciences's portfolio in Q2 2026, its #70 holding.
  • PFM Health Sciences first reported a position in Arcus Biosciences in Q1 2018 and has held it in 20 quarters since.
  • PFM Health Sciences's Arcus Biosciences position peaked at $139M in Q4 2021.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.